WO2009042962A3 - Antidotes for factor xa inhibitors and methods of using the same - Google Patents
Antidotes for factor xa inhibitors and methods of using the same Download PDFInfo
- Publication number
- WO2009042962A3 WO2009042962A3 PCT/US2008/078014 US2008078014W WO2009042962A3 WO 2009042962 A3 WO2009042962 A3 WO 2009042962A3 US 2008078014 W US2008078014 W US 2008078014W WO 2009042962 A3 WO2009042962 A3 WO 2009042962A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- antidotes
- inhibitors
- methods
- same
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title abstract 3
- 239000000729 antidote Substances 0.000 title abstract 3
- 229940075522 antidotes Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108010074860 Factor Xa Proteins 0.000 abstract 2
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 abstract 2
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000000701 coagulant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 108010014806 prothrombinase complex Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Priority Applications (39)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08834136.7T ES2597436T3 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor Xa inhibitors and procedures for their use |
PL16167534T PL3078743T3 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
BRPI0816837-7A BRPI0816837B1 (en) | 2007-09-28 | 2008-09-26 | PHARMACEUTICAL COMPOSITIONS, ISOLATED TWO-CHAIN POLYPEPTIDE AND USE OF A PHARMACEUTICAL COMPOSITION |
KR1020177023761A KR20170100071A (en) | 2007-09-28 | 2008-09-26 | ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME |
EP08834136.7A EP2193196B1 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
KR1020167003860A KR102069498B1 (en) | 2007-09-28 | 2008-09-26 | ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME |
EP16167534.3A EP3078743B1 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
BR122022001846-7A BR122022001846B1 (en) | 2007-09-28 | 2008-09-26 | USE OF TWO-CHAIN POLYPEPTIDE FOR DRUG PREPARATION TO REDUCE BLEEDING |
CN2008801079738A CN101802188B (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
EP14197779.3A EP2915564B1 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor XA inhibitors and methods of using the same |
NZ583944A NZ583944A (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
LTEP08834136.7T LT2193196T (en) | 2007-09-28 | 2008-09-26 | ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME |
KR1020107008718A KR101698214B1 (en) | 2007-09-28 | 2008-09-26 | ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME |
DK08834136.7T DK2193196T3 (en) | 2007-09-28 | 2008-09-26 | Clinical profile of Factor Xa inhibitors, and methods of use thereof |
CA2697583A CA2697583C (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
PL14197779T PL2915564T3 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor XA inhibitors and methods of using the same |
KR1020207001549A KR102271404B1 (en) | 2007-09-28 | 2008-09-26 | ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME |
AU2008304192A AU2008304192B9 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor Xa inhibitors and methods of using the same |
JP2010527220A JP5637561B2 (en) | 2007-09-28 | 2008-09-26 | Antidote to factor Xa inhibitor and method of use thereof |
MX2010003095A MX2010003095A (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same. |
EP20198287.3A EP3824902A1 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
SI200831678A SI2193196T1 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
IL203993A IL203993A (en) | 2007-09-28 | 2010-02-16 | Antidotes for factor xa inhibitors and methods of using the same |
ZA2010/02039A ZA201002039B (en) | 2007-09-28 | 2010-03-23 | Antidotes for factor xa inhibitors and methods of using the same |
AU2013205326A AU2013205326A1 (en) | 2007-09-28 | 2013-04-11 | Antidotes for factor XA inhibitors and methods of using the same |
HRP20161255TT HRP20161255T1 (en) | 2007-09-28 | 2016-10-03 | Antidotes for factor xa inhibitors and methods of using the same |
CY20161101020T CY1118482T1 (en) | 2007-09-28 | 2016-10-12 | CONDITIONS FOR THEIR SUSPENSIONS AND METHODS FOR USE |
AU2017200212A AU2017200212A1 (en) | 2007-09-28 | 2017-01-12 | Antidotes for factor XA inhibitors and methods of using the same |
IL255397A IL255397B (en) | 2007-09-28 | 2017-11-02 | Antidotes for factor xa inhibitors and methods of using the same |
IL264886A IL264886B (en) | 2007-09-28 | 2019-02-18 | Antidotes for factor xa inhibitors and methods of using the same |
AU2019204123A AU2019204123A1 (en) | 2007-09-28 | 2019-06-13 | Antidotes for factor XA inhibitors and methods of using the same |
NO2019040C NO2019040I1 (en) | 2007-09-28 | 2019-11-08 | andexane alpha |
IL272926A IL272926A (en) | 2007-09-28 | 2020-02-26 | Antidotes for factor xa inhibitors and methods of using the same |
CY20201100715T CY1123504T1 (en) | 2007-09-28 | 2020-08-04 | ANTIDOTES FOR FACTOR HA INHIBITORS AND METHODS OF USING THEM |
NL301063C NL301063I2 (en) | 2007-09-28 | 2020-09-09 | Andexanet alpha |
FR20C1045C FR20C1045I2 (en) | 2007-09-28 | 2020-09-23 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USE THEREOF |
NO2020033C NO2020033I1 (en) | 2007-09-28 | 2020-09-23 | andexane alpha |
LTPA2020540C LTC3078743I2 (en) | 2007-09-28 | 2020-12-22 | ANTIBODIES TO FACTOR XA INHIBITORS AND THEIR USE |
AU2021218033A AU2021218033A1 (en) | 2007-09-28 | 2021-08-17 | Antidotes for factor XA inhibitors and methods of using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97634307P | 2007-09-28 | 2007-09-28 | |
US60/976,343 | 2007-09-28 | ||
US9057408P | 2008-08-20 | 2008-08-20 | |
US61/090,574 | 2008-08-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009042962A2 WO2009042962A2 (en) | 2009-04-02 |
WO2009042962A3 true WO2009042962A3 (en) | 2009-06-04 |
WO2009042962A9 WO2009042962A9 (en) | 2009-09-11 |
Family
ID=40481812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/078014 WO2009042962A2 (en) | 2007-09-28 | 2008-09-26 | Antidotes for factor xa inhibitors and methods of using the same |
Country Status (27)
Country | Link |
---|---|
US (8) | US8153590B2 (en) |
EP (4) | EP3078743B1 (en) |
JP (6) | JP5637561B2 (en) |
KR (4) | KR20170100071A (en) |
CN (4) | CN101802188B (en) |
AU (6) | AU2008304192B9 (en) |
BR (2) | BRPI0816837B1 (en) |
CA (1) | CA2697583C (en) |
CY (2) | CY1118482T1 (en) |
DK (3) | DK2193196T3 (en) |
ES (3) | ES2597436T3 (en) |
FR (1) | FR20C1045I2 (en) |
HK (1) | HK1210443A1 (en) |
HR (2) | HRP20161255T1 (en) |
HU (4) | HUE050063T2 (en) |
IL (4) | IL203993A (en) |
LT (3) | LT2193196T (en) |
MX (1) | MX2010003095A (en) |
NL (1) | NL301063I2 (en) |
NO (2) | NO2019040I1 (en) |
NZ (1) | NZ583944A (en) |
PL (3) | PL2915564T3 (en) |
PT (3) | PT2193196T (en) |
SG (1) | SG185263A1 (en) |
SI (3) | SI2915564T1 (en) |
WO (1) | WO2009042962A2 (en) |
ZA (2) | ZA201002039B (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
BRPI0711296A2 (en) | 2006-05-05 | 2011-08-23 | Millennium Phamaceutical Inc | xa factor inhibitors |
CN101802188B (en) * | 2007-09-28 | 2013-08-21 | 普托拉制药有限公司 | Antidotes for factor xa inhibitors and methods of using the same |
EP2364165B1 (en) | 2008-11-14 | 2018-01-03 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
AU2009327338B2 (en) * | 2008-12-19 | 2015-07-02 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
EP2414517B1 (en) * | 2009-03-30 | 2016-09-21 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
WO2011008885A1 (en) * | 2009-07-15 | 2011-01-20 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
EP2316931B1 (en) * | 2009-10-30 | 2016-12-28 | Senova Gesellschaft für Biowissenschaft und Technik mbH | Polymer-coupled peptidases |
WO2011075602A1 (en) | 2009-12-17 | 2011-06-23 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
CA2784921A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
TWI513466B (en) * | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | Anticoagulant antidotes |
NZ603028A (en) | 2010-03-19 | 2014-11-28 | Baxter Healthcare Sa | Tfpi inhibitors and methods of use |
TW201240664A (en) * | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
WO2012098089A1 (en) | 2011-01-19 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Binding proteins to inhibitors of coagulation factors |
FR2972114B1 (en) * | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | A NEW MOLECULAR LURE PROCOAGULANT FOR THE TREATMENT OF HEMOPHILS A OR B WITH OR WITHOUT INHIBITOR |
BR112013025031A2 (en) | 2011-03-30 | 2017-08-01 | Boehringer Ingelheim Int | anticoagulant antidotes |
US9371522B2 (en) * | 2011-09-30 | 2016-06-21 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
AP2014007662A0 (en) * | 2011-11-29 | 2014-05-31 | Perosphere Inc | Anticoagulant reversal agents |
JP2015507929A (en) | 2012-02-14 | 2015-03-16 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Process for making a recombinant antagonist against a factor Xa inhibitor |
WO2013123248A1 (en) | 2012-02-16 | 2013-08-22 | Portola Pharmaceuticals, Inc. | MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE |
NZ724133A (en) | 2012-03-21 | 2020-07-31 | Baxalta Inc | Tfpi inhibitors and methods of use |
ES2612458T3 (en) * | 2012-06-14 | 2017-05-17 | Portola Pharmaceuticals, Inc. | Procedure for purification of recombinant factor Xa derivatives |
US9145552B2 (en) | 2012-07-25 | 2015-09-29 | Catalyst Biosciences, Inc. | Modified factor X polypeptides and uses thereof |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
FR3000895B1 (en) * | 2013-01-11 | 2017-02-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | USE OF ANTIDOTES OF COAGULATION INHIBITORS INDICATED IN THE PREVENTION OR TREATMENT OF THROMBOEMBOLIC PATHOLOGIES |
US20150352194A1 (en) * | 2013-01-24 | 2015-12-10 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
MX2015008813A (en) | 2013-01-31 | 2016-03-31 | Pfizer | Compositions and methods for counteracting factor xa inhibition. |
FR3007410B1 (en) * | 2013-06-21 | 2016-05-27 | Lab Francais Du Fractionnement | FACTOR X DEPRIVED WITH DOMAINE GLA |
MX2016003871A (en) * | 2013-09-24 | 2016-08-04 | Pfizer | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins. |
EP3063170A4 (en) * | 2013-11-01 | 2017-06-28 | The Children's Hospital of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
CA2949349A1 (en) | 2014-05-26 | 2015-12-03 | Academisch Ziekenhuis Leiden | Prohemostatic proteins for the treatment of bleeding |
WO2016019145A1 (en) * | 2014-07-31 | 2016-02-04 | Haemonetics Corporation | Detection and classification of an anticoagulant using a clotting assay |
US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
EA036091B1 (en) * | 2014-08-20 | 2020-09-25 | Портола Фармасьютикалз, Инк. | AQUEOUS FORMULATIONS OF FACTOR Xa (fXa) ANTIDOTES FOR PREVENTING OR REDUCING BLEEDING AND USE THEREOF |
CN105030703B (en) * | 2015-06-23 | 2018-03-23 | 上海旭东海普药业有限公司 | A kind of razaxaban piece of anti-treatment embolism class diseases and preparation method thereof |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
WO2017147522A1 (en) | 2016-02-24 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
US10640822B2 (en) | 2016-02-29 | 2020-05-05 | Iridia, Inc. | Systems and methods for writing, reading, and controlling data stored in a polymer |
CN109415766A (en) * | 2016-02-29 | 2019-03-01 | 艾瑞迪亚公司 | Method, composition and device for information storage |
US10859562B2 (en) | 2016-02-29 | 2020-12-08 | Iridia, Inc. | Methods, compositions, and devices for information storage |
US10438662B2 (en) | 2016-02-29 | 2019-10-08 | Iridia, Inc. | Methods, compositions, and devices for information storage |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
HUE054597T2 (en) | 2016-06-17 | 2021-09-28 | Alexion Pharma Inc | Preparation of factor xa derivatives |
WO2018115235A1 (en) | 2016-12-22 | 2018-06-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antidotes to anti-coagulant drugs allowing diagnosis and treatment |
KR102616666B1 (en) | 2016-12-23 | 2023-12-27 | 노파르티스 아게 | Factor XI Antibodies and Methods of Use |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
EP3672520A4 (en) * | 2017-08-21 | 2021-06-30 | Allele Biotechnology And Pharmaceuticals, Inc. | Light-absorbing compositions and methods of use |
WO2019096874A1 (en) | 2017-11-15 | 2019-05-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
US20210371842A1 (en) * | 2018-06-19 | 2021-12-02 | Alexion Pharmaceuticals, Inc. | Antidotes to factor xa inhibitors |
CA3109007A1 (en) * | 2018-08-14 | 2020-02-20 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition and preparation method therefor |
US11655465B1 (en) | 2019-05-02 | 2023-05-23 | Iridia, Inc. | Enzymes and systems for synthesizing DNA |
US20220251534A1 (en) * | 2019-08-08 | 2022-08-11 | Alexion Pharmaceuticals, Inc. | Compositions and methods for preparing factor xa and derivatives |
US11837302B1 (en) | 2020-08-07 | 2023-12-05 | Iridia, Inc. | Systems and methods for writing and reading data stored in a polymer using nano-channels |
CN113484386B (en) * | 2021-05-21 | 2024-02-13 | 郑州轻工业大学 | Preparation method and application of metal phthalocyanine nano material, aptamer sensor and preparation method thereof |
CN114681597A (en) * | 2022-03-11 | 2022-07-01 | 兆科药业(合肥)有限公司 | Application of viper venom hemocoagulase in preparation of drugs for reversing anticoagulation of coagulation factor Xa inhibitor |
CN116327627B (en) * | 2023-03-10 | 2024-06-07 | 四川大学 | Tetrahedral framework nucleic acid-glabridin complex and application thereof in skin whitening |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000577A1 (en) * | 1994-06-29 | 1996-01-11 | Cor Therapeutics, Inc. | Agents affecting thrombosis hemostasis |
US5589572A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
US5795863A (en) * | 1990-09-04 | 1998-08-18 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
WO1998038318A1 (en) * | 1997-02-27 | 1998-09-03 | Baxter Aktiengesellschaft | Factor x deletion mutants and analogues thereof |
WO1998039456A1 (en) * | 1997-03-07 | 1998-09-11 | Washington University | Factor x variant |
EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH596313A5 (en) * | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP0590689B2 (en) | 1985-03-30 | 2006-08-16 | KAUFFMAN, Stuart A. | Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombinant technique |
US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5278144A (en) * | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
WO1992013878A2 (en) | 1991-02-07 | 1992-08-20 | Board Of Trustees Of The University Of Illinois | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
PL171489B1 (en) | 1991-09-13 | 1997-05-30 | Chiron Corp | Method of obtaining an immunogenous composition capable to immunologically cross-react with many hcv isolates |
WO1993009804A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
DE4203965A1 (en) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | ANTIDOT FOR HIRUDIN AND SYNTHETIC THROMBIN INHIBITORS |
US6117836A (en) | 1992-03-20 | 2000-09-12 | Cor Therapeutics, Inc. | Glycosylation-mediated inhibition of factor X |
ATE304604T1 (en) | 1993-06-24 | 2005-09-15 | Frank L Graham | ADENOVIRUS VECTORS FOR GENE THERAPY |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
SK283703B6 (en) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
DE4430205A1 (en) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Compositions suitable as antidotes for blood anticoagulants and their use |
AT404357B (en) | 1995-06-13 | 1998-11-25 | Immuno Ag | PROTHROMINE DERIVATIVES |
US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
DE19605126A1 (en) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombin muteins as an antidote for thrombin inhibitors |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
SE9604744D0 (en) | 1996-12-20 | 1996-12-20 | Pharmacia & Upjohn Ab | A modified coagulation agent |
AT405516B (en) | 1997-02-27 | 1999-09-27 | Immuno Ag | FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT |
JPH1149800A (en) | 1997-06-05 | 1999-02-23 | Fujimori Kogyo Kk | Synthesis of anhydrothrombin |
DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
JP2002530081A (en) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | Antibody variants with higher binding affinity than the parent antibody |
WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
US6258559B1 (en) | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
US6858599B2 (en) | 1999-06-30 | 2005-02-22 | Mochida Pharmaceutical Co., Ltd. | Tricyclic compound having spiro union |
AT411997B (en) * | 1999-09-14 | 2004-08-26 | Baxter Ag | FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES |
EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
WO2001068605A1 (en) | 2000-03-13 | 2001-09-20 | Pharmacia Corporation | Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade |
MXPA03002049A (en) | 2000-09-08 | 2003-07-24 | Schering Corp | Mammalian genes; related reagents and methods. |
US7070740B1 (en) | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
US20030064414A1 (en) | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
WO2002090599A1 (en) | 2001-05-09 | 2002-11-14 | Genetic Id, Inc. | Universal microarray system |
US6989267B2 (en) | 2001-07-02 | 2006-01-24 | Agilent Technologies, Inc. | Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films |
DE10155075A1 (en) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Cyclic sulfonamides |
US6861236B2 (en) | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
CN1480466A (en) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | Interfusion protein possessing dual functions of thrombolysis and anticoagulation as well as its application |
US20040198660A1 (en) | 2002-11-06 | 2004-10-07 | Petersen Lars Christian | Tissue factor antagonist and protein C polypeptide compositions |
US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
WO2005088310A2 (en) | 2004-03-05 | 2005-09-22 | The Scripps Research Institute | High throughput glycan microarrays |
JP4441336B2 (en) | 2004-06-11 | 2010-03-31 | 日本碍子株式会社 | Manufacturing method of microarray |
US9223929B2 (en) | 2005-03-14 | 2015-12-29 | The California Institute Of Technology | Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays |
US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
US9164108B2 (en) | 2005-03-22 | 2015-10-20 | Sri International | Liposome-based microarray and methods of use thereof |
PT1948608E (en) | 2005-11-08 | 2012-05-24 | Millennium Pharm Inc | Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor |
MX2008006313A (en) * | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Reactive dyestuffs, method for the production thereof, and use of the same. |
US20070111322A1 (en) | 2005-11-15 | 2007-05-17 | Lin-Cheng Yang | Novel method of using inject printing for creating microarrays |
CN101802188B (en) * | 2007-09-28 | 2013-08-21 | 普托拉制药有限公司 | Antidotes for factor xa inhibitors and methods of using the same |
EP2364165B1 (en) * | 2008-11-14 | 2018-01-03 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
WO2010070137A1 (en) | 2008-12-19 | 2010-06-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
EP2414517B1 (en) * | 2009-03-30 | 2016-09-21 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
WO2011008885A1 (en) * | 2009-07-15 | 2011-01-20 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
-
2008
- 2008-09-26 CN CN2008801079738A patent/CN101802188B/en active Active
- 2008-09-26 KR KR1020177023761A patent/KR20170100071A/en not_active Application Discontinuation
- 2008-09-26 DK DK08834136.7T patent/DK2193196T3/en active
- 2008-09-26 HU HUE16167534A patent/HUE050063T2/en unknown
- 2008-09-26 LT LTEP08834136.7T patent/LT2193196T/en unknown
- 2008-09-26 CN CN201310301566.3A patent/CN103446579B/en active Active
- 2008-09-26 CN CN201110447251.0A patent/CN102559644B/en active Active
- 2008-09-26 DK DK16167534.3T patent/DK3078743T3/en active
- 2008-09-26 SG SG2012072716A patent/SG185263A1/en unknown
- 2008-09-26 ES ES08834136.7T patent/ES2597436T3/en active Active
- 2008-09-26 CN CN2011104472050A patent/CN102533702A/en active Pending
- 2008-09-26 JP JP2010527220A patent/JP5637561B2/en active Active
- 2008-09-26 PL PL14197779T patent/PL2915564T3/en unknown
- 2008-09-26 WO PCT/US2008/078014 patent/WO2009042962A2/en active Application Filing
- 2008-09-26 KR KR1020167003860A patent/KR102069498B1/en active IP Right Grant
- 2008-09-26 MX MX2010003095A patent/MX2010003095A/en active IP Right Grant
- 2008-09-26 HU HUE14197779A patent/HUE052423T2/en unknown
- 2008-09-26 KR KR1020207001549A patent/KR102271404B1/en active IP Right Grant
- 2008-09-26 EP EP16167534.3A patent/EP3078743B1/en active Active
- 2008-09-26 DK DK14197779.3T patent/DK2915564T3/en active
- 2008-09-26 HU HUE08834136A patent/HUE031647T2/en unknown
- 2008-09-26 KR KR1020107008718A patent/KR101698214B1/en active IP Right Grant
- 2008-09-26 EP EP20198287.3A patent/EP3824902A1/en active Pending
- 2008-09-26 PT PT88341367T patent/PT2193196T/en unknown
- 2008-09-26 BR BRPI0816837-7A patent/BRPI0816837B1/en active IP Right Grant
- 2008-09-26 PT PT161675343T patent/PT3078743T/en unknown
- 2008-09-26 PL PL08834136T patent/PL2193196T3/en unknown
- 2008-09-26 EP EP14197779.3A patent/EP2915564B1/en active Active
- 2008-09-26 CA CA2697583A patent/CA2697583C/en active Active
- 2008-09-26 SI SI200832153T patent/SI2915564T1/en unknown
- 2008-09-26 AU AU2008304192A patent/AU2008304192B9/en active Active
- 2008-09-26 SI SI200831678A patent/SI2193196T1/en unknown
- 2008-09-26 NZ NZ583944A patent/NZ583944A/en unknown
- 2008-09-26 ES ES16167534T patent/ES2796623T3/en active Active
- 2008-09-26 PL PL16167534T patent/PL3078743T3/en unknown
- 2008-09-26 LT LTEP16167534.3T patent/LT3078743T/en unknown
- 2008-09-26 PT PT141977793T patent/PT2915564T/en unknown
- 2008-09-26 EP EP08834136.7A patent/EP2193196B1/en active Active
- 2008-09-26 ES ES14197779T patent/ES2849426T3/en active Active
- 2008-09-26 BR BR122022001846-7A patent/BR122022001846B1/en active IP Right Grant
- 2008-09-26 SI SI200832130T patent/SI3078743T1/en unknown
- 2008-09-26 US US12/239,651 patent/US8153590B2/en active Active
-
2010
- 2010-02-16 IL IL203993A patent/IL203993A/en active IP Right Grant
- 2010-03-23 ZA ZA2010/02039A patent/ZA201002039B/en unknown
-
2012
- 2012-03-07 US US13/414,499 patent/US8455441B2/en active Active
-
2013
- 2013-04-11 AU AU2013205326A patent/AU2013205326A1/en not_active Abandoned
- 2013-05-07 US US13/889,014 patent/US9062298B2/en active Active
- 2013-06-11 US US13/915,525 patent/US8889129B2/en active Active
-
2014
- 2014-07-21 US US14/337,074 patent/US9388401B2/en active Active
- 2014-08-07 AU AU2014210620A patent/AU2014210620B2/en active Active
- 2014-08-19 JP JP2014166333A patent/JP6047127B2/en active Active
- 2014-09-04 ZA ZA2014/06514A patent/ZA201406514B/en unknown
-
2015
- 2015-11-13 HK HK15111214.0A patent/HK1210443A1/en unknown
-
2016
- 2016-06-08 US US15/176,461 patent/US10675335B2/en active Active
- 2016-10-03 HR HRP20161255TT patent/HRP20161255T1/en unknown
- 2016-10-12 CY CY20161101020T patent/CY1118482T1/en unknown
- 2016-11-18 JP JP2016225290A patent/JP6300885B2/en active Active
-
2017
- 2017-01-12 AU AU2017200212A patent/AU2017200212A1/en not_active Abandoned
- 2017-11-02 IL IL255397A patent/IL255397B/en active IP Right Grant
-
2018
- 2018-02-27 JP JP2018033229A patent/JP2018100290A/en active Pending
-
2019
- 2019-02-18 IL IL264886A patent/IL264886B/en active IP Right Grant
- 2019-06-13 AU AU2019204123A patent/AU2019204123A1/en not_active Abandoned
- 2019-11-08 NO NO2019040C patent/NO2019040I1/en unknown
-
2020
- 2020-02-26 IL IL272926A patent/IL272926A/en unknown
- 2020-03-12 JP JP2020042919A patent/JP2020109113A/en active Pending
- 2020-05-07 US US16/869,117 patent/US11839646B2/en active Active
- 2020-07-08 HR HRP20201071TT patent/HRP20201071T1/en unknown
- 2020-08-04 CY CY20201100715T patent/CY1123504T1/en unknown
- 2020-09-09 NL NL301063C patent/NL301063I2/en unknown
- 2020-09-23 FR FR20C1045C patent/FR20C1045I2/en active Active
- 2020-09-23 NO NO2020033C patent/NO2020033I1/en unknown
- 2020-12-22 HU HUS2000057C patent/HUS2000057I1/en unknown
- 2020-12-22 LT LTPA2020540C patent/LTC3078743I2/en unknown
-
2021
- 2021-08-17 AU AU2021218033A patent/AU2021218033A1/en active Pending
-
2022
- 2022-07-29 JP JP2022121451A patent/JP2022153574A/en active Pending
-
2023
- 2023-11-02 US US18/500,675 patent/US20240082367A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795863A (en) * | 1990-09-04 | 1998-08-18 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
WO1996000577A1 (en) * | 1994-06-29 | 1996-01-11 | Cor Therapeutics, Inc. | Agents affecting thrombosis hemostasis |
US5589572A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
WO1998038318A1 (en) * | 1997-02-27 | 1998-09-03 | Baxter Aktiengesellschaft | Factor x deletion mutants and analogues thereof |
WO1998039456A1 (en) * | 1997-03-07 | 1998-09-11 | Washington University | Factor x variant |
EP1820508A1 (en) * | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
Non-Patent Citations (3)
Title |
---|
SCHULMAN ET AL: "Anticoagulants and Their Reversal", TRANSFUSION MEDICINE REVIEWS, GRUNE AND STRATTON, ORLANDO, FL, US, vol. 21, no. 1, 13 December 2006 (2006-12-13), pages 37 - 48, XP005749419, ISSN: 0887-7963 * |
TINEL HANNA ET AL: "Partial reversal of the anticoagulant effect of high-dose rivaroxaban An oral, direct factor Xa inhibitor - by recombinant factor VIIa in rats.", BLOOD, vol. 108, no. 11, Part 1, November 2006 (2006-11-01), & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, pages 274A, XP009115121, ISSN: 0006-4971 * |
YOUNG GUY ET AL: "Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography", BLOOD COAGULATION & FIBRINOLYSIS, vol. 18, no. 6, 1 September 2007 (2007-09-01), pages 547 - 553, XP009115120, ISSN: 0957-5235 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009042962A3 (en) | Antidotes for factor xa inhibitors and methods of using the same | |
WO2010056765A3 (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
TN2009000132A1 (en) | Substituted dihydropyrazolones for treating cardiovascular and haematological diseases | |
TR201820051T4 (en) | Use of Anti-factor XI Antibodies for Prevention or Treatment of Thrombus Formation | |
WO2008124384A3 (en) | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
TR201909189T4 (en) | C-KIT KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS | |
EA200901486A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | |
WO2009154840A3 (en) | Compositions and methods using stem cells in cutaneous wound healing | |
EA201100335A8 (en) | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-ASSOCIATED DISEASES | |
WO2011115712A3 (en) | Tfpi inhibitors and methods of use | |
WO2009079451A3 (en) | Compositions and methods of promoting wound healing | |
WO2008127654A3 (en) | Methods and compositions for intra-articular coagulation proteins | |
WO2010017196A3 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
ECSP10010494A (en) | DIHYDROPIRAZOLONAS REPLACED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASE | |
WO2009158031A3 (en) | Methods and compositions for therapeutic treatment | |
WO2013061083A3 (en) | Therapeutic agents and uses thereof | |
WO2008103345A3 (en) | Hemostatic compositions and therapeutic regimens | |
GB2462228A (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
WO2010071894A3 (en) | Tfpi inhibitors and methods of use | |
WO2007117560A8 (en) | Piperidine and morpholine renin inhibitors | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
EA200901484A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | |
MX2014010940A (en) | The use of antithrombin in the treatment of pre-eclampsia. | |
MX2015001508A (en) | The use of antithrombin in extracorporeal membrane oxygenation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880107973.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08834136 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 203993 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2697583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008304192 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 583944 Country of ref document: NZ Ref document number: 962/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010527220 Country of ref document: JP Ref document number: MX/A/2010/003095 Country of ref document: MX |
|
REEP | Request for entry into the european phase |
Ref document number: 2008834136 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008834136 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008304192 Country of ref document: AU Date of ref document: 20080926 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107008718 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0816837 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100318 |